SPDL1 and pancreatic neoplasm: However, in an analysis using sPD-L1, Kruger et al. reported that sPD-L1 did not predict adverse outcomes in patients with advanced pancreatic cancer (11.92 months for high sPD-L1-expressing patients vs. 9.53 months for low sPD-L1-expressing patients, P = 0.36).